Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) Gross Profit (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Gross Profit readings, the most recent being $170.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit fell 0.86% year-over-year to $170.2 million, compared with a TTM value of $901.5 million through Dec 2025, up 35.85%, and an annual FY2025 reading of $901.5 million, up 35.85% over the prior year.
  • Gross Profit hit $170.2 million in Q4 2025 for Apellis Pharmaceuticals, down from $434.0 million in the prior quarter.
  • The five-year high for Gross Profit was $434.0 million in Q3 2025, with the low at $5.5 million in Q3 2021.
  • Median Gross Profit over the past 5 years was $107.2 million (2023), compared with a mean of $113.3 million.
  • The sharpest move saw Gross Profit crashed 67.23% in 2022, then skyrocketed 540.72% in 2023.
  • Year by year, Gross Profit stood at $60.2 million in 2021, then tumbled by 67.23% to $19.7 million in 2022, then soared by 540.72% to $126.5 million in 2023, then surged by 35.75% to $171.7 million in 2024, then dropped by 0.86% to $170.2 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $170.2 million, $434.0 million, and $164.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.